JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) marked an important juncture in. BNP in 11, participants without cardiovascular disease in the JUPITER Un Estudio Intervencionista que Evalúa Rosuvastatina (JUPITER, Justification. Desde que en el estudio JUPITER 34 se detectó una mayor incidencia de DM en el grupo con rosuvastatina 35, varios metaanálisis han.

Author: Voodoolmaran Samujas
Country: Greece
Language: English (Spanish)
Genre: Medical
Published (Last): 28 October 2007
Pages: 162
PDF File Size: 19.35 Mb
ePub File Size: 5.23 Mb
ISBN: 596-4-98898-420-9
Downloads: 21108
Price: Free* [*Free Regsitration Required]
Uploader: JoJosho

It must be noted that the study was non-comparative and open label. A randomised controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: Furthermore the combination of rosuvastatin with fenofibric acid was well tolerated and as safe as each drug used as monotherapy. Abstract Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties.

Studies comparing different lipid lowering regimens demonstrate that only high impact therapy with rosuvastatin 40 mg or atorvastatin 80 mg achieves this goal when administered as monotherapy. Previously, there has been limited data on statin benefits in women, black and Hispanic patients. No fee has been received for preparation of the manuscript. In conclusion rosuvastatin is an effective and safe statin which is ideal second line treatment for most patients requiring primary or secondary prevention.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

The 4S study showed that simvastatin 20 mg to 40 mg daily significantly reduced major coronary events, coronary death and overall mortality in patients post-MI or those with ischaemic heart disease. These results indicate the potential value of genetic profiling of patients to optimise statin response in a cost effective manner.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease Study of Heart and Renal Protection: There are no known drug interactions between rosuvastatin and non nucleoside reverse transcriptase inhibitors NNRTIs. Early detection and treatment with statins has been shown to reduce morbidity and mortality in those with heterozygous familial hypercholesterolaemia.

You may also like -  LINKSYS RE2000 PDF

There were significant estudo in non fatal acute myocardial infarction and in other esttudio composite endpoints, with no difference in cardiovascular or all-cause mortality. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: Use of Rosuvastatin versus Atorvastatin in type 2 diabetes mellitus.

When hsCRP is included in enrolment of primary prevention, rosuvastatin produced greater benefit when compared with other statins.

A number of reports are emerging about intermittent or pulsed therapy which is better tolerated yet maintains reasonable lipid control. Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique estuddio and pharmacokinetic properties. The highest risk was associated with fluvastatin while pravastatin and rosuvastatin had the lowest risks.

Special groups Patients with hereditary hyperlipidaemia, particularly FH and FCH should be considered for early treatment with rosuvastatin.

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. When there rosuvastatinx a history of previous statin intolerance or multiple drug therapy, low dose rosuvastatin may be considered.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial rowuvastatina. Intermittent rosuvastatin Several small studies have reported that alternate-day therapy with rosuvastatin has important benefits in addition to improving the lipid profile. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages.

Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.

The use of rosuvastatin did however reduce hospitalisation from cardiovascular causes. A randomised double blind double-dummy, multicentre, phase IIIb, parallel-group study to compare the efficacy and safety of rosuvastatin 10 mg and 20 mgand atorvastatin 10 mg and 20 mg rosuvasyatina patients with type 2 diabetes mellitus ANDROMEDA showed that rosuvastatin produced greater reductions in LDL-C, ApoB and total cholesterol when compared with equal doses of atorvastatin.

You may also like -  DAMA CU CAMELII EPUB

This does not reduce the cholesterol lowering potency; therefore rosuvastatin can be taken with or without food, and in the morning or evening.

Rosuvastatin which is a new generation HMG-CoA reductase inhibitor exhibits some unique pharmacologic and pharmacokinetics properties. The trial was stopped after a median follow-up of 1. Rediscovering bile acid sequestrants.

Other HMG-CoA reductase inhibitors are either natural, mevinic acid derived lovastatin, simvastatin, pravastatin or synthetic, heptenoic acid derived atorvastatin, fluvastatin. A large retrospective cohort jupier in America found that rosuvastatin produced the largest reduction in LDL-C, non-HDL-C and triglycerides when compared with atorvastatin and pravastatin.

The affinity of rosuvastatin for the active site of the enzyme is four times greater than the affinity of HMG-CoA for the enzyme.

Furthermore these patients are at extremely high cardiovascular risk. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes.

Effect of two intensive statin regimens on progression of coronary disease. Several small studies have reported that alternate-day therapy with rosuvastatin has important rosuuvastatina in addition to improving the lipid profile.

Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. Diabetes Research and Clinical Practice. Unrestricted non-commercial use is permitted provided the original work uupiter properly cited.

Rosuvastatina y el estudio Jupiter. by Ybel Fermin on Prezi

An Assessment of Survival and Cardiovascular Events. Economic evaluations show that intensive lipid lowering is a cost effective treatment for very high risk patients groups including those with ACS, heterozygous FH and diabetes. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.

Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top